Wellington et al. invest €7.5m in ImevaX

Santo Venture Capital, EMBL Ventures and BioMedPartners took part in the round, with the latter investing via its CHF 106m BioMedInvest II fund.

ImevaX will use the capital to push its lead candidate, IMX-101, through clinical trials.

Santo is the venture arm of the Strüngmann family office, Athos Service.

Company
Munich-based ImevaX span out of the Technische Universität München earlier this year. The company develops vaccines for pathogens of chronic infectious diseases.

Its current lead candidate, IMX-101, is a vaccine designed to treat helicobacter pylori, a bacteria that causes stomach ulcers and gastric cancer.

People
Volker Wedershoven is the CEO of ImevaX, having taken the position in September. Markus Gerhard is the company's founder and chief scientific officer.

Wellington partner Erich Schlick has joined the company's board of directors alongside BioMed partner Markus Hosang, EMBL managing director Jan Adams and Ulrich Granzer of Granzer Regulatory Consulting.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Wellington Partners
• Germany